Pitched as saving lives by extending free breast screening to women aged 70–74 (previously 45–69).

The Policy: National Breast Screening Policy — 2023 Election →

Why it was proposed:

• Risk rises with age: a woman's risk of breast cancer is actually higher at 70 than at 50, yet free screening previously stopped at 69. Modelling for the Breast Cancer Foundation found older women who keep screening have a 42% lower risk of dying from breast cancer (Te Whatu Ora).
• An ageing population sharpens the case: the 65+ group grew to about 842,000 by 2020, passes 1 million by 2028, and reaches roughly 1.34–1.46 million by 2048 (Stats NZ).
• Equity: breast-cancer outcomes have been worse for Māori and Pacific women; the extension, paired with a new opt-out system (Te Puna) that surfaced about 135,000 under-screened women, aims to close coverage gaps as well as add years of eligibility.

By the numbers:

• About 130,000 more women become eligible (every two years), roughly 54,000 extra screens a year once fully rolled out.
• Around 350 women aged 70–74 are diagnosed each year; the extension is expected to catch about 60 more cancers a year at an earlier, more treatable stage.
• Context: NZ records about 3,878 breast-cancer registrations and 650+ deaths a year — among the highest incidence rates in the world (Breast Cancer Foundation NZ).

Does it join up with the rest of the system?

• Detection meets treatment: catching tumours at stage 1 or 2 is exactly when the new and widened therapies from the $604m Pharmac boost work best — so screening and the medicines funding reinforce each other.
• Screening capacity is being built for it: the four-year phasing is deliberate, and Health NZ is resourcing it with seven new mammography machines, ultrasound gear, four new mobile units and new fixed sites (Kāpiti Coast, Takapuna, Greenlane), plus radiographer and radiologist recruitment (RNZ).
• The remaining question is downstream: more detection adds to surgery and oncology demand while elective-surgery waitlists are already blown out and the Dunedin hospital rebuild was scaled back — so the screening build-out still needs hospital capacity to match.

The result (in progress):

Phased from October 2024 (pilot) to full coverage by 2029. Verdict: a deliberately staged, well-resourced and evidence-backed extension that reinforces the Pharmac investment and targets equity gaps — with its full payoff still hinging on downstream hospital and surgical capacity.